HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Li, Y. Articles by Zhou, L. Search for Related Content PubMed PubMed Citation Articles by Li, Y. Articles by Zhou, L.

Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma

All authors from department of Hematology, Changzheng Hospital, the second hospital affiliated to the Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China

Correspondence: Jian Hou, Department of Hematology, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China. E-mail: houjian167{at}sohu.com

In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p<0.05). Similar results were also observed in the Thal+Dex cohort. For the first time, our primary data suggested that the polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in MM.

Key words: thalidomide, multiple myeloma, CYP2C19 genotype, efficacy.